Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19

Inclusion Criteria: 1. Age ≥ 18 years. 2. History of or type 2 diabetes mellitus or a diagnosis of type 2 diabetes during hospitalization. 3. Confirmation of infection with SARS-CoV-2 by PCR testing. 4. Patients within 10 days from symptom onset or patients within 48 hours after laboratory diagnosis (SARS-CoV-2 PCR). Exclusion Criteria: 1. WHO COVID-19 Ordinal Scale for Clinical Improvement ≥ 6. 2. Respiratory failure requiring mechanical ventilation prior to randomization. 3. Use of vasopressor or inotropic medications prior to randomization. 4. Intolerance/hypersensitivity to dipeptidyl peptidase-4 inhibitors. 5. Patients expected to require intensive care unit admission or immediate surgical intervention. 6. Participation in another trial assessing any treatment for COVID-19. 7. Current treatment with a DPP-4 inhibitor. 8. Pregnancy.